Results 71 to 80 of about 239,171 (309)

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

Basal Cell Carcinoma of the Penis: A Case Report and Review of the Literature

Case Reports in Urology, 2014
Basal cell carcinoma of the penis is an extremely rare entity, accounting for less than 0.03% of all basal cell carcinomas. Fortunately, wide local excision of such lesions is generally curative.
R. J. Roewe, Matthew A. Uhlman, Nathan A. Bockholt, Amit Gupta   +3 more
doaj   +1 more source

Fine needle aspiration cytology of basal cell adenoma of parotid simulating adenoid cystic carcinoma

Journal of Cytology, 2018
Basal cell adenoma is a rare type of monomorphic salivary adenoma most commonly involving the parotid gland. Cytology of basal cell adenoma closely mimics many other benign and malignant basaloid neoplasms.
Subrata Pal, Palash Kr Mondal, Abhishek Sharma, Mrinal Sikder   +3 more
doaj   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Pigmented basal cell carcinoma

Pigment International
Pigmented basal cell carcinoma (pBCC) is an uncommon clinical and histopathological variant that is more frequent in darker skin types. The increased number of melanocytes and the subsequent melanin production are responsible for the increased ...
Vijayasankar Palaniappan, Anusuya Sadhasivamohan, Kaliaperumal Karthikeyan   +2 more
doaj   +1 more source

Giant basal cell carcinoma associated with vitiligo

Clinical Case Reports, 2019
We report a woman with two giant Basal cell carcinomas (BCCs) on the back, the largest with 12 cm in diameter, inside a vitiligo plaque. They were metatypical subtype BCC associated with a nodular subtype area.
Luiza Fiszon‐Cerqueira, Marcia Ramos‐e‐Silva, Flávio Bacelar Guerreiro, Marcela Cistaro‐Serrano, Ana Helena Correia Carneiro, Maria Kátia Gomes   +5 more
doaj   +1 more source

Investigational agents in metastatic basal cell carcinoma: focus on vismodegib

, 2012
Nicolas Batty,1 Ellen Kossoff,2 Grace K Dy11Department of Medicine, Roswell Park Cancer Center, Buffalo, NY, USA; 2Department of Pharmacy, Roswell Park Cancer Center, Buffalo, NY, USAAbstract: Vismodegib (GDC-0449, 2-chloro-N-(4-chloro-3-(pyridin-2-yl ...
Batty N, Kossoff E, Dy GK
core  

Vismodegib: the Proof of Concept in Basal Cell Carcinoma

, 2014
Although basal cell carcinoma (BCC) is the most common cancer worldwide, its metastatic dissemination is exceptional. Before 2012, we had a few treatment options available for metastatic or locally advanced cases.
Siham Lkhoyali, Narjiss Berrada, Hassan Errihani, Hind Mrabti   +3 more
core   +1 more source

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source